BIO Unveils Action Plan for U.S. Biotech Leadership

The Biotechnology Innovation Organization (BIO) released an action plan titled BioAdvance: Securing America's Biotech Century to help the United States remain the global leader in biotechnology, following China's new five-year strategy targeting the sector as a national pillar industry. The proposal outlines seven specific priorities for Congress and the administration to address competition from Beijing, which has invested heavily in its own drugmaking force while conducting more clinical trials faster and cheaper than U.S. counterparts. Key elements of this action plan include accelerating drug development timelines, improving domestic clinical trial infrastructure, attracting investment, supporting biomedical research, and establishing a White House Office of Biotechnology to coordinate these efforts. BIO President John Crowley emphasized that the current moment requires the same ambition that drove America's original biotech revolution to counter China's rapid ascent as a major force in medicine.